Close Menu

NEW YORK – Biocept said on Tuesday that it has entered into a securities purchase agreement with several institutional investors for the issuance and sale of 22.3 million shares of its common stock at a price of $0.46 per share, for aggregate gross proceeds of approximately $10.3 million, in a registered direct offering.

Maxim Group is acting as the sole placement agent for the offering, which is expected to close on or about April 16.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.